About Lazurite
Lazurite is a company based in Cleveland (United States) founded in 2015 by Eugene Malinskiy and Ilya Malinskiy. Lazurite has raised $12.92 million across 3 funding rounds. The company has 17 employees as of December 31, 2021. Lazurite offers products and services including ArthroFree 2, Wireless Receiver, Battery and Charger, and Meridiem Image Enhancer. Lazurite operates in a competitive market with competitors including Augmedics, Proprio, ClearPoint Neuro, IMRIS Deerfield Imaging and eCential Robotics, among others.
- Headquarter Cleveland, United States
- Employees 17 as on 31 Dec, 2021
- Founders Eugene Malinskiy, Ilya Malinskiy
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lazurite Holdings Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$12.92 M (USD)
in 3 rounds
-
Latest Funding Round
$1.66 M (USD), Seed
Dec 26, 2024
-
Investors
Not available
-
Employee Count
17
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Lazurite
Lazurite offers a comprehensive portfolio of products and services, including ArthroFree 2, Wireless Receiver, Battery and Charger, and Meridiem Image Enhancer.
Delivers HD wireless imaging for arthroscopy procedures.
Enables secure wireless video transfer in surgeries.
Provides long-lasting power for surgical devices.
Optimizes surgical image clarity and sharpness.
People of Lazurite
Unlock access to complete
Unlock access to complete
Funding Insights of Lazurite
Lazurite has successfully raised a total of $12.92M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $1.66 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Lazurite
Investment portfolio details for Lazurite
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Lazurite
Detailed financials for Lazurite
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lazurite Comparisons
Peer comparison for Lazurite
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lazurite
Lazurite operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Augmedics, Proprio, ClearPoint Neuro, IMRIS Deerfield Imaging and eCential Robotics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Augmented reality systems for guiding surgical procedures are developed.
|
|
| Locked | Locked | Locked |
Visualization systems for surgical procedures are developed using machine learning.
|
|
| Locked | Locked | Locked |
Software and hardware solutions for MRI-guided surgical planning are provided.
|
|
| Locked | Locked | Locked |
Surgical theatres with ceiling mounted mobile imaging devices to enhance intraoperative workflow
|
|
| Locked | Locked | Locked |
Robotic surgery platform for bone procedures is developed.
|
|
| Locked | Locked | Locked |
Developer of a device for tumor localization
|
Detailed competitors of Lazurite
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lazurite
Complete news archive for Lazurite
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lazurite
Lazurite was founded in 2015.
Lazurite is headquartered in Cleveland, United States. It is registered at Cleveland, Ohio, United States.
Lazurite is a funded company, having raised a total of $12.92M across 3 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Lazurite is 17.
Lazurite was founded in 2015 in Cleveland, United States, within the medical devices sector. Arthroscopic tools are developed by the company to address joint-related issues through minimally invasive procedures. The modular ArthroFree wireless camera system is provided for surgical applications, while the Meridiem light engine supports signal transmission, power delivery, and illumination within the ArthroFree setup. Operations focus on innovative hardware for orthopedic interventions.
Lazurite's top competitors include Augmedics, Proprio and ClearPoint Neuro.
Lazurite offers ArthroFree 2, Wireless Receiver, Battery and Charger, and Meridiem Image Enhancer.